TabsDetailsBasic DetailsDate Posted: Monday, October 30, 2017Status: CompleteMedical Product: dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylureaHealth Outcome(s): diabetestype 1 diabetes mellitustype 2 diabetes mellitusDescription: This report contains the estimated number of new users of Sodium/Glucose Cotransporter (SGLT-2) Inhibitors, Sulfonylureas, and Dipeptidyl peptidase-4 (DPP-4) Inhibitors among all users overall, users with Type I diabetes codes, and users with Type II diabetes codes. Read More Deliverables (1)Sentinel Modular Program Report: SGLT2 InhibitorsAdditional InformationAdditional DetailsFDA Center: CDERTime Period: April 1, 2013 - September 30, 2015Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: 2017 ICPE Poster: Type 1 and Type 2 Diabetes Mellitus Identification Using ICD-9-CM Codes Within a Cohort of New Users of Drugs Labeled for Type 2 Diabetes Mellitus
